Evren Technologies, Inc

Advancing PTSD Treatment with an FDA Breakthrough Device

Evren Technologies, Inc

Advancing PTSD Treatment with an FDA Breakthrough Device

Closing in 11 days
Gainesville, FL
Biotechnology
Health Tech
Evren Technologies is developing a discrete earbud that utilizes a groundbreaking treatment for PTSD to help people easily manage their symptoms and improve outcomes. Backed by clinical evidence, the Phoenix® improves patient health and well-being with fewer side effects and higher patient engagement than seen with current prescription drugs and therapies.*

$220,784

raised
95
Investors
$15.1M
Valuation
$6.65
Price per Share
$399.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
11
Days Left

$220,784

raised
95
Investors
$15.1M
Valuation
$6.65
Price per Share
$399.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
11
Days Left
invest now

Rewards

Get rewarded for investing more into Evren Technologies, Inc:

StartEngine OWNERS Exclusive Click here to learn more

$399+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Select this Bonus

$1,000+
Investment
Investor | $1,000+
Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).

Select this Bonus

$5,000+
Investment
Watt | $5,000+
Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).

Select this Bonus

$10,000+
Investment
Franklin | $10,000+
Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).

Select this Bonus

$25,000+
Investment
Edison | $25,000+
Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).

Select this Bonus

$50,000+
Investment
Tesla | $50,000+
Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).

Reasons to Invest

Large market: $20B+ market opportunity addressing 15M Americans.
Experienced Leadership: Management team with a proven track record, including 9 successful exits, $150M+ raised, and 6 FDA-cleared devices.
Validated Technology: FDA Breakthrough Device Designation, nearly $500K in non-dilutive funding from the Department of Defense and National Institute of Mental Health.

Evren Technologies currently has a working prototype of the Phoenix® earbud and a beta version of the accompanying app

*Information based on internal research with resources provided by the National Center for PTSD (  source)

A Groundbreaking Treatment for PTSD

Millions are suffering from PTSD each year, but current treatments simply aren’t enough, leaving 66% of patients seeking better treatment options.



This is why we’re creating the Phoenix®, a non-invasive, affordable, and drug-free treatment for PTSD. The Phoenix is an innovative earbud device that will deliver personalized vagal nerve stimulation (VNS) to reduce PTSD severity and improve quality of life without the harmful side effects of prescription drugs. The pilot trial results were exceptional, earning the Phoenix Breakthrough Device Designation from the FDA. More importantly, PTSD patients loved the device. 100% of pilot trial participants wanted to keep their device after the trial, even those who achieved remission.


The device reduces PTSD severity, which includes symptoms such as  depression, anxiety, insomnia, nightmares & flashbacks, social avoidance, and suicidality — and does so with no significant side effects. The Phoenix was recently awarded Breakthrough Device Designation by the FDA based on early clinical data, and we’re now ready to launch it into the next phase of development as we look to serve those chronically suffering from PTSD. 

The Problem


Current Treatments Aren’t Enough

Despite millions of Americans dealing with PTSD on a daily basis, far too many patients are still looking for relief. 15M Americans are impacted by PTSD in a typical year, and the pandemic has been far from typical, with rates soaring as high as 60M.


(source)


Despite millions of Americans dealing with PTSD on a daily basis, far too many patients are still looking for relief. The primary treatment option is antidepressants, which can cause increased suicidality and are intended only for short-term use. 


Therapy, another common treatment in the patient roadmap, is more time and resource-intensive than many people can afford, and still lacks proper research, phenotyping, and individualization—oftentimes worsening symptoms. Researchers and academics agree that current therapies are inadequate, indicating a pressing need for new approaches to the issue.

The Solution


A Better Way to Treat PTSD

*The above rendering is a computer generated simulation.


The Phoenix will treat PTSD by stimulating the vagus nerve with a light electrical tingle, providing personalized dosing based on stress levels. It is completely non-invasive and has no significant adverse side effects. It's portable and discrete, allowing for treatment anywhere you need it. In short, it will empower users to take back control of their lives.


The result? PTSD patients love the Phoenix! 100% of users wanted to keep using the Phoenix after the pilot study and all of them were willing to pay out-of-pocket for it. Here is what they had to say:



*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.

The Market


$22.5B Addressable Market Opportunity

PTSD is an enormous global market, valued at $22.5B in the US alone.* The Phoenix is an extremely scalable technology at the forefront of 2 of the fastest growing medical device markets: Bioelectronic Medicine and Wearable Medical Devices.

*Information based on internal research done by Evren Technologies



Our Traction


FDA designation, NIMH and DoD funding, and an Elite Team

Since Evren started in 2019, we’ve made great strides and have seen a phenomenal response from both PTSD patients and governing agencies. 


  • FDA Breakthrough Device Designation
  • $256,000 in funding from the National Institute of Mental Health
  • $222,000 in funding from the Department of Defense

This traction has allowed Evren to assemble an elite team of leading experts in PTSD, VNS, and military healthcare.




In the Press

Why Invest


Working towards a better future for those suffering from PTSD

We envision a better future for those suffering from PTSD—though it doesn’t stop there. The Phoenix is an extremely scalable technology, with vagal nerve stimulation approved for the treatment of many other disorders, including epilepsy, opioid withdrawal, major depressive disorder, and migraines, with potential application for a longer list that includes anxiety, insomnia, long COVID and traumatic brain injury. 


Join us on our mission to improve countless lives, enable a happier, healthier future, and empower patients to #RiseAbovePTSD.


*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.

Offering Summary


Company

:

Evren Technologies, Inc

Corporate Address

:

404 SW 140th Terrace, Suite 50, Gainesville, FL 32669

Offering Minimum

:

$9,994.95

Offering Maximum

:

$1,069,998.30

Minimum Investment Amount

(per investor)

:

$399.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

1,503

Maximum Number of Shares Offered

:

160,902

Price per Share

:

$6.65

Pre-Money Valuation

:

$15,085,870.80











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based

Friends and Family Early Birds

Invest within the first 72 hours and receive 15% bonus shares.

Early Bird Bonus

Invest within the first week (7 calendar days) and receive 10% bonus shares.

Amount-Based

Investor | $1,000+

Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).

Watt | $5,000+

Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).

Franklin | $10,000+

Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).

Edison | $25,000+

Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).

Tesla | $50,000+

Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Evren Technologies, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $6.65 / share, you will receive 110 shares Common Stock, meaning you'll own 110 shares for $665. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Insider Investment Notice

Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$202,707.00 USD
$116,875.00 USD
Cash And Cash Equivalents
$64,269.00 USD
$13,388.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$436,215.00 USD
$514,900.00 USD
Long Term Debt
$150,000.00 USD
$150,000.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
$14,956.00 USD
-$418,616.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

Updates

Need Another Reason to Invest? Ask Thomas!

22 hours ago

Read this moving testimonial from one of our recent investors detailing why he decided to support Evren Technologies’s mission. 


"I invested in Evren Technologies because I have suffered from Major Depressive Disorder for almost 23 years. I know there is a huge unmet need for better PTSD, depression, and anxiety treatments. 


The technology that Evren has developed and manufactured is groundbreaking and exciting. First, to know that so many people could receive such a simple but effective treatment is encouraging, especially without needing health insurance. Secondly, the type of device that Evren has developed is convenient and side-effect free.


The unmet need for better PTSD treatment is huge. So many of our country’s military men and women are being affected mentally. After sacrificing their lives, families, and time, they deserve the best treatment options available.


With the onset of the pandemic in 2020, and the fallout that has occurred, mental illness is reaching all time high levels. More treatments like The Phoenix device need to be made readily available to ALL that need it, regardless of financial or health insurance status.


As someone who suffers from mental illness, I think it’s wonderful what Evren Technologies has developed for those suffering from PTSD. I would love to see Evren Technologies take treatment to a new level. I would also like to see Evren’s device indications expand, to treat depression, anxiety, personality disorders, schizophrenia, and all types of mental illness.


To me, it’s a privilege and pleasure, to be able to aid in furthering Evren Technologies’s research and development." - Thomas Warrington


Pilot study participants saw an average 18.4 pt reduction in CAPS-5. No wonder 100% of our participants wanted to keep The Phoenix earbud!  


Visit our raise page on StartEngine to learn more about our mission to enable a happier, healthier future for people with PTSD. 



Warmly,
Weaver Gaines
CEO
Evren Technologies


“This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.”

Don’t Miss Evren’s Farewell Webinar!

3 days ago


Are you on the fence about potentially investing or considering reinvesting in Evren Technologies? Tomorrow is your last chance to speak to CEO Weaver Gaines about exciting developments in Evren’s future. 


Don’t miss our live Q&A investor webinar on August 16th at 4:00 pm EDT! There is only 1 day left to register! 


PTSD is an underserved $22.5B market which leaves 66% of patients still seeking relief through new treatment solutions. Evren Technologies was recently awarded a Breakthrough Device Designation by the FDA for demonstrating the Phoenix can better alleviate symptoms than current available therapies with no side effects. 


15 million adults in the U.S. suffer from PTSD every year, and by investing in Evren Technologies, you can contribute to making a real difference in their lives. 


Sign up today for one final, farewell webinar with the Evren Team before our campaign closes. 


Remember to share our raise page with your network so they can learn more about investment opportunities!



Warmly,
Weaver Gaines
CEO
Evren Technologies

Only 2 Weeks Left to Invest in Evren!

3 days ago


Time is becoming increasingly limited to invest in our StartEngine campaign. 


There are only 2 weeks left to get in on the ground floor of the company developing the revolutionary Phoenix earbud - an all in one system designed to alleviate the symptoms of PTSD. .  


PTSD is an underserved, $22.5 Billion-dollar market with 66% of those suffering currently seeking new treatment solutions. 15 Million Americans will suffer from PTSD in any given year, and over 60 million had PTSD during the height of the COVID shutdown.


Now is the time to invest in a revolutionary treatment designed to combat PTSD symptoms - with no side effects. 100% of trial participants wanted to keep the device!


We envision a better future for people suffering from PTSD, and with the growing support of investors like you, we can make this dream a reality.


Learn more about joining our investor community by visiting our raise page today. Please help spread the word by sharing with your friends, family, and network! 



Warmly,
Weaver Gaines
CEO
Evren Technologies

Last Webinar Only 3 Days Away!

5 days ago

Hello Evren Community!


Don’t miss your last chance to chat with Evren’s CEO, Weaver Gaines! He is hosting a final investor Q&A webinar before our StartEngine campaign ends. 


There are only 3 days left to register!


Reserve your spot today to chat with the Evren team on August 16th at 4:00pm EDT.


With the continuous support of our growing inverter community, Evren Technologies is primed to take on the next stages of research and development for our revolutionary technologies. 


Evren’s Phoenix earbud has been shown to alleviate symptoms of PTSD without adverse side effects, greatly improving patients’ quality of life. 


Together with investors like you, we are helping people rise above PTSD by alleviating debilitating symptoms. 


Please share this amazing opportunity with your friends, family, and network. 



Warmly,
Weaver Gaines
CEO
Evren Technologies

Heal From Trauma With The Phoenix by Evren Technologies!

6 days ago

Millions of Americans suffer from the debilitating symptoms that come from surviving trauma. PTSD affects everyone differently, but many experience extreme anxiety, depression, anger, social isolation, insomnia, and suicidality. Symptoms can interfere with someone’s interpersonal relationships and even prevent them from being able to work. Living with panic and flashbacks can leave a person too exhausted to conduct their daily lives. 


Unfortunately, most of the current treatments available don’t do enough to eliminate symptoms of PTSD. Over 66% of patients who begin therapy are still seeking relief from their most persistent symptoms. 


In our clinical trials, an astounding 100% of participants experienced reduced symptoms and wanted to keep the device! Overall, participants experienced up to a 91% decrease in symptoms. 


Recently, the Phoenix was awarded a Breakthrough Device Designation by the FDA, which will help us fast track our trials. Evren Technologies is dedicated to helping alleviate symptoms of PTSD for millions of people. We continue to further research in this developing field and develop new technologies to help people rise above PTSD. 


PTSD treatment is a $22.5B market that continues to grow every year. You can help us provide relief to those who need it most by investing in Evren Technologies for as little as $399. 


With the help of our growing investor community, we can alleviate the suffering of people with PTSD everywhere. 


Visit our raise page on StartEngine today to learn more about the benefits of investing in Evren Technologies. Please share with your friends, family, and network! 


Warmly,

Weaver Gaines

CEO

Evren Technologies

VNS was Featured in the NY Times!

7 days ago


Check out this recent article on Vagal Nerve Stimulation (VNS) in the New York Times! Read about how this revolutionary technology is changing lives. Evren Technologies was featured in the New York Times in June.

 

Our wellbeing is dependent on a functional and adaptive nervous system. PTSD leads to a maladaptive system, which makes people feel unsafe all the time. The key to regulating the safety response is the vagus nerve, which basically controls the safety response.


The Phoenix delivers stimulation to the auricular branch of the vagus nerve through the ear, bringing it back into balance. This allows PTSD victims to finally feel safe again.


The continued coverage of VNS by major publications is a testament to the rapid growth of the field. This is your chance to get in at the ground floor by investing in Evren, one of the top biotech campaigns on StarEngine!


Join our mission to create a brighter future for those struggling with debilitating symptoms. Visit our raise page on StartEngine to learn about the perks of early investment. Please share this great opportunity with your family, friends, and network.


Together, we can ease suffering and help people rise above PTSD!




Warmly,
Weaver Gaines
CEO
Evren Technologies

Only 5 Days Til Our Last Webinar!

7 days ago


There are only 5 days left until CEO Weaver Gaines hosts his final webinar. Join us and learn about why our Phoenix earbud was awarded an FDA Breakthrough Device Designation and what this means for the future of Evren Technologies. 


With 100% of trial participants wanting to keep the device after the studies ended, this revolutionary device is primed to significantly improve the lives of people suffering from PTSD. 


Register today for our live webinar on August 16th at 4:00pm EDT to reserve your spot.


This is your last chance to personally ask your investor questions before our StartEngine campaign ends. 


We invite you to share our webinar with your friends, family, and network. 


Warmly,
Weaver Gaines
CEO
Evren Technologies

Why Invest in Evren? Ask Susan!

8 days ago

There are many great reasons to join the Evren team, as seen by our steadily growing investor community. Here’s a recent testimonial from one of our investors explaining what convinced her to support Evren Technologies’s mission to help people rise above PTSD.


“I invested because those with PTSD need a better option. In my opinion, The Phoenix® earbud is that option. Society needs to move away from prescription drugs. This technology could give the PTSD community a drug free option that truly works. Thank you to the entire Evren Team for dedicating their time and efforts to such a great cause.” - Susan Hughes, Investor


PTSD is an underserved $22.5B market in the U.S. alone, affecting over 15 million people. The Phoenix® earbud uses vagus nerve stimulation therapy to help the 66% of patients still seeking relief from symptoms of PTSD. 


Early clinical trials show this noninvasive earbud can reduce symptoms with no significant side effects, earning The Phoenix® a Breakthrough Device Designation by the FDA. 


Now is a great time to join our mission to improve countless lives, enable a happier, healthier future, and empower patients. 


Remember to share this opportunity with your network!



Warmly,
Weaver Gaines
CEO
Evren Technologies


“This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.”

This is Your Last Chance to Chat!

9 days ago


Don’t miss your last chance to ask your investor questions directly to the CEO of Evren himself, Weaver Gaines. This will be his final webinar before Evren’s StartEngine campaign comes to a close. 


Register today for our live webinar on August 16th at 4:00pm EDT to reserve your spot.


Evren’s Phoenix earbud provides personalized levels of vagal nerve stimulation to significantly reduce symptoms of PTSD while improving quality of life - without harmful side effects. 


Learn how you can get in on the ground floor of this revolutionary technology. 


We invite you to share our webinar with your friends, family, and network. 



Warmly,
Weaver Gaines
CEO
Evren Technologies

This is Your Last Chance!

16 days ago


Hello Evren Community!


Join CEO Weaver Gaines and the Evren Team for a final webinar before our StartEngine campaign ends. 


Have all your questions about PTSD, vagus nerve stimulation therapy, and investment opportunities answered! 


Register today for our live webinar on August 16th at 4:00 pm EDT!


Don’t miss out! This is your last chance to talk to Evren Technologies’s CEO Weaver Gaines live before our campaign comes to a close. 


Visit our raise page to learn how you can be part of this exciting technology. 


Help make a difference by sharing Evren’s mission with your family, friends, and network. 


Warmly,
Weaver Gaines
CEO
Evren Technologies


Only 1 Month Left on StartEngine!

20 days ago


We’ve entered the final month of our campaign on StartEngine. 


There is only 1 month left, and we still need your help to reach our goal! 


Evren Technologies is dedicated to improving the lives of soldiers afflicted with Acute Stress Reactions. In April of 2022, Evren Technologies was awarded a $172K contract from the military in order to support soldier safety and performance. 


Benefits of early investing include:


  • $1,000+ Investment - 50% off device

  • $5,000+ Investment - 5% Bonus Shares + 50% off device

  • $10,000+ Investment - 10% Bonus Shares + 50% off 2 devices

  • $25,000+ Investment - 20% Bonus Shares + 50% off 3 devices

  • $50,000+ Investment - 25% Bonus Shares + 50% off 4 devices


We envision a better future for people suffering from PTSD, and with help from investors like you, we can make this dream a reality.


Learn more about joining our investor community by visiting our raise page. Please help spread the word by sharing with your friends, family, and network! 



Warmly,

Weaver Gaines
CEO
Evren Technologies

Help us get to $300K!

about 1 month ago


Hello Evren Community! 


We're just under $98,755K away from reaching $300K investments, and we need your help to get us there! 


Evren is developing a device, the Phoenix®, which will reduce PTSD symptom severity by stimulating the vagus nerve, vastly improving the patient’s quality of life.


Why Invest? 

  • $20B+ market opportunity addressing at least 15M Americans.

  • Able to improve quality of life by an average of 38% for responders*.

  • Breakthrough Device Designation from the FDA, awarded over $250K in grant funding from the NIH. 

  • Management team with a proven track record, including 9 successful exits, $150M+ raised, and a combined 100 years of experience.


Help us bring comfort to the 15M Americans suffering from PTSD each year by investing in Evren Technologies on our raise page today.


Warmly,
Weaver Gaines
CEO
Evren Technologies

Our Community Joins In! | Insider Investment Notice

about 1 month ago

We’re excited to see our community come in and invest in Evren Technologies!

Our insiders have invested $8,305.85 into this offering since the last Insider Investment Notice.


We hope you join us on our mission to create a better treatment for PTSD. Invest in Evren today!

Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.

Have You Seen Our Perks?

about 1 month ago


Evren Technologies uses the latest research and development to create an effective new treatment for PTSD. Using groundbreaking vagus nerve stimulation therapy, the Phoenix earbud will help people easily manage their symptoms and improve recovery outcomes.


Evren Technologies is dedicated to improving the lives of soldiers afflicted with Acute Stress Reactions. In April of 2022, Evren Technologies was awarded a $172K contract from the military in order to support soldier safety and performance. 


Even with current therapies and medications, 66% of patients are still seeking new solutions to alleviate their symptoms. You can help millions of people suffering from debilitating symptoms of PTSD. 


Benefits of early investing include:

  • $1,000+ Investment - 50% off device

  • $5,000+ Investment - 5% Bonus Shares + 50% off device

  • $10,000+ Investment - 10% Bonus Shares + 50% off 2 devices

  • $25,000+ Investment - 20% Bonus Shares + 50% off 3 devices

  • $50,000+ Investment - 25% Bonus Shares + 50% off 4 devices



The PTSD treatment market is $22.5B in the U.S. alone with approximately 15M people suffering symptoms every year. Our device leverages improvements on existing technologies, allowing for easier use and better results. 


We envision a better future for people suffering from PTSD and with help from investors like you, we can make this dream a reality. 

Read more about investment opportunities by visiting our raise page.



Warmly,

Weaver Gaines
CEO
Evren Technologies



Together we can Rise Above PTSD!

about 1 month ago


Hello, 


Countless Americans have PTSD, yet 66% are still seeking relief from persistent symptoms. People can experience extreme anxiety, depression, anger, social isolation, insomnia, interpersonal difficulties, and suicidality. Current treatments include cognitive behavioral therapy, which can take months or even years to noticeably work. Medications available can be addicting or provide minimal relief, with only 20% of patients fully recovering. Longterm, PTSD can contribute to a variety of health conditions and even prevent a person from working. 


Promising new research has discovered vagus stimulation therapy can drastically alleviate debilitating symptoms. Evren Technologies has designed a non-invasive earbud device that delivers this revolutionary FDA approved treatment. The Phoenix is a portable device that delivers a light electrical tingle to your vagus nerve, inducing a calming effect to help reduce symptoms of PTSD. There are no side effects and the device only needs to be worn a few minutes throughout the day. 


“My therapist says I’ve completely changed” - Samantha


Evren Technologies is excited to further research and development of this amazing new treatment option. Clinical trials have shown participants experienced up to a 91% decrease in their most prominent symptoms and 100% wanted to continue using The Phoenix. 


“My wife says she has her husband back and our kids have their dad back” - Andy“


I feel like I have a healthy balance with everything that made me unbalanced before” - Kano


PTSD treatment is a $22.5B market and is increasing every year. You can now become a part of this exciting technology and help make a true difference in the lives of the millions suffering from PTSD. Our mission is to empower people to rise above PTSD through wearable neuromodulation products. 


Read more about how to become an early investor for as little as $399 by visiting our website. The Phoenix was recently awarded a Breakthrough Device Designation by the FDA and we are excited to launch into the next phase of development. Together, we can rise above PTSD! 


Warmly,

Weaver Gaines

CEO

Evren Technologies



Notice of Material Change in Offering

about 2 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Evren Technologies, Inc offering. Here's an excerpt describing the specifics of the change:

Issuer is extending campaign end date.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Evren: MHSRS

about 2 months ago


Hello Evren Community! 


We are excited to announce that Evren will be attending this year’s MHSRS! This event is the Department of Defense’s foremost scientific symposium. It is an annual four-day educational symposium that draws approximately 3,500 attendees. 


This event provides a venue for presenting new scientific knowledge resulting from military-unique research and development. One great example is our product - the Phoenix!


Evren Technologies is developing the Phoenix, a discrete earbud that utilizes our groundbreaking treatment for PTSD. 


Read our recent blog to learn more.


Warmly,

Weaver Gaines

Awarded MTEC Grant!

about 2 months ago


Hello Evren Community! 


We were awarded the prestigious Medical Technology Enterprise Consortium (Army in partnership with the DOD) grant for quality system implementation!


This grant will allow the advancement of PTSD treatment and related conditions through wearable neurostimulation products. 


The Phoenix® will be a discrete earbud that utilizes our groundbreaking treatment for PTSD. Backed by clinical evidence, the Phoenix® improves patient health and well-being with fewer side effects and higher patient engagement than seen with current prescription drugs and therapies.


Please spread the word about our investment opportunity to your friends, family and network!



Warmly,

Weaver Gaines
CEO
Evren Technologies



Evren’s CEO Webinar is Only 1 Day Away!

2 months ago


A final, friendly reminder that our webinar is only 1 day away! Hosted by Evren Technologies CEO Weaver Gaines, who is ready to answer all your investor questions! 


Learn why you don’t want to miss out on this $22B market opportunity (bioelectronic medicine and PTSD)!


Join us live this Friday, June 17th, 2022 at 1:00 PM PST!


Our live Q&A investor webinar is tomorrow, so be sure to reserve your spot today! 


Some perks for becoming an early investor are: 


  • $1,000+ Investment- 50% off device 

  • $5,000+ Investment - 5% bonus shares + 50% off device

  • $10,000+ Investment - 10% bonus shares + 50% off 2 devices

  • $25,000+ Investment - 20% bonus shares + 50% off 3 devices

  • $50,000+ Investment - 25% bonus shares + 50% off 4 devices


Sign up to register for our live webinar today! Please help spread the word by sharing this email with your network!


Visit our raise page on StartEngine to learn more!


Warmly,

Weaver Gaines
CEO
Evren Technologies



New York Times Mentions Evren Technologies!

2 months ago


Evren Technologies has some exciting news! Recently, Dr. Eric Porges was mentioned in a New York Times article featuring the revolutionary vagus nerve stimulation therapy. 


The Phoenix is a noninvasive, portable device that delivers a light electrical tingle to your vagus nerve, inducing a calming effect shown to reduce symptoms of PTSD with no side effects. 


Evren Technologies is changing how people recover from trauma, and we’re excited to pursue further research and development  for this amazing new treatment. 


We need investors like you to help us reach our goal of alleviating symptoms for the millions of people suffering from PTSD. The current treatment market for this industry is $22.5B a year and is still growing annually. 


Help us make a real difference in PTSD research and help people around the world rise above PTSD. 


You can become an early investor for as little as $399! 


Visit our raise page on StartEngine to learn about more perks of becoming an early investor. 



Warmly,

Weaver Gaines
CEO
Evren Technologies



Evren Invites You to Our Webinar June 17th!

2 months ago


We are thrilled to invite you to our live Q&A webinar one week away, hosted by Evren CEO Weaver Gaines! 


Join us live on Friday, June 17th, at 1:00 PM PST! 


There is only one week remaining to register for our investor webinar. I will be ready to discuss what makes Evren Technologies a great investment opportunity and answer all your questions! 


Sign up to register for Evren’s investor Q&A webinar today! 


I am looking forward to sharing with you the perks of becoming an early investor and how Evren Technologies can help millions of people struggling with persistent symptoms of PTSD! 


Warmly,

Weaver Gaines
CEO
Evren Technologies




Only 5 Days Remaining Until Evren’s Live Webinar!

2 months ago


We are thrilled to invite you to our live webinar this Friday, hosted by Evren CEO Weaver Gaines! 


Join us live on Friday, June 17th, at 1:00 PM PST!


There are only 5 days left to register for our investor Q&A webinar. I will be ready to discuss why Evren Technologies is a great investment opportunity and answer all your questions! 


Sign up to register for Evren’s investor Q&A webinar today! 


I’m looking forward to sharing the benefits of becoming an early investor, and discussing how you can aid Evren Technologies’ mission to help millions of people struggling with persistent symptoms of PTSD! 


Visit our raise page on StartEngine to learn more about our investor community!



Warmly,

Weaver Gaines
CEO
Evren Technologies




Celebrating $200K Investments!

2 months ago


Hello Evren Community! 


Now, this is something worth bragging about! The Evren team is ecstatic to announce we’ve reached $200K investments!


It can be tough living with PTSD. At Evren, we feel it is our mission to create solutions that work for people to easily manage their symptoms and improve outcomes. This is why we are developing a discrete earbud that will be a groundbreaking, non-drug treatment for PTSD!



Why should you invest?


  • Be a  part of the PTSD global market valued at $20B+.

  • We're addressing the 15M Americans suffering from PTSD.

  • Successful, passionate management team with 100 years of combined experience.


We encourage all current investors to reinvest and to spread the word about our investment opportunity on StartEngine!



Warmly,

Weaver Gaines
CEO
Evren Technologies



Less Than 2 Weeks Until Evren’s Informative CEO Webinar!

2 months ago


My name is Weaver Gaines, CEO of Evren Technologies. I will be hosting an informative investor Q&A webinar on Friday, June 17th, 2022 at 1:00 PM PST and invite you all to attend! 


There are less than two weeks remaining until I go live to answer all your questions, so be sure to register today!


Evren Technologies is dedicated to developing our discrete earbud that utilizes a groundbreaking treatment to alleviate distressing symptoms of PTSD. 


Supported by clinical evidence, the Phoenix earbud drastically improves both patient health and well-being with fewer side effects and higher patient engagement than currently available treatment options! 


Millions of people struggle with persistent symptoms of PTSD. 


The Phoenix was recently granted an FDA Breakthrough Device Designation for demonstrating the capability to significantly reduce PTSD symptoms and give people their lives back.


Register for our webinar here and please help spread the word! 


Come prepared to ask questions by reading more about our goals by visiting our StartEngine raise page. 


Together, we can empower patients to rise above PTSD!  



Warmly,

Weaver Gaines
CEO
Evren Technologies



Exclusive Investor Q&A Recap!

2 months ago


Evren Technologies Community, 


Evren Technologies is on a mission to help people rise above PTSD.


We recently held an investor webinar where we shared the amazing results of our PTSD trial with the Phoenix device - which made the FDA award Evren a breakthrough device designation!!


In case you missed it, we encourage you to check out our recent  webinar recap video!


If you have any questions that are still left unanswered, do not hesitate to reach out to our team! We will be more than happy to assist you.


If you haven’t already done so, we encourage you to reinvest and help us reach our milestones sooner.


Thank you for your continued support and belief in our mission!


Warmly,

Weaver Gaines

CEO

Evren Technologies



Our Scientific Board of Advisors is Growing!

3 months ago


It is our pleasure to announce that Dr. J. Douglas Bremner has joined our Scientific Advisory Board. Dr. Bremner attended medical school at Duke University, followed by residency in Psychiatry and Nuclear Medicine at Yale. He is currently a professor of psychiatry and the director of the Emory Clinical Neuroscience Research Unit at Emory University School of Medicine. Dr. Bremner’s research has used neuroimaging and neurobiology measures to study PTSD related to combat and childhood abuse, and he has authored/co-authored over 200 peer reviewed articles. Evren Technologies is thrilled to have Dr. Bremner’s counsel as we work towards our goal: to relieve the suffering of millions with this disabling condition.  We are confident that his advice will propel our Phoenix towards nothing less than groundbreaking improvements in the way we treat PTSD. 


Warmly,

Weaver Gaines
CEO
Evren Technologies



Evren Technologies is Offering Bonus Shares!

3 months ago


Evren Technologies Community,


Ready to invest into Evren Technologies, Inc.?


We’ve designed a number of perks where you receive extra capital based on your investment amount - buy more shares, get more shares!


Here’s the list of perks that you can also find on our StartEngine raise page:


  • $399+ Investment - This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section on our raise page.


  • $1,000+ Investment (Investor) - Receive 50% off device purchase (coupon for use once the product is available on the market).


  • $5,000+ Investment (Watt) - Receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).


  • $10,000+ Investment (Franklin) - Receive 10% bonus shares + 50% off 2 device purchases (coupon for use once the product is available on the market).


  • $25,000+ Investment (Edison) - Receive 20% bonus shares + 50% off 3 device purchases (coupon for use once the product is available on the market).


  • $50,000+ Investment (Tesla) - Receive 25% bonus shares + 50% off 4 device purchases (coupon for use once the product is available on the market).


What are you waiting for? Head over to our raise page and take advantage of this opportunity while time permits!


Our executive team would like to thank you in advance for your support.



Warmly,

Weaver Gaines

Notice of Material Change in Offering

4 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Evren Technologies, Inc offering. Here's an excerpt describing the specifics of the change:

Campaign is extending by 60 days and updating 2020/2021 financials

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Tomorrow! Live Q&A Webinar With Dr. Richard Marshall.

4 months ago


Hello Evren Community! 👋


Join us tomorrow for our live investor Q&A webinar with Dr. Richard Marshall at 12:00 PM PST/3:00 PM EST!


This is your last chance to register before we go live.


Our discussion will be focused on trauma, PTSD and VNS. We hope to see you there! You can register for the webinar here.


We encourage everyone to spread the word to their network about investing and joining this exclusive online event!



Warmly,

Weaver Gaines
CEO
Evren Technologies




Live Q&A Webinar With Dr. Richard Marshall!

4 months ago


Hello Evren Community! 


Join Evren Technologies and Dr. Richard Marshall for a live investor Q&A webinar April 29th at 12:00 PM PST/3:00 PM EST.


There are only 3 days left to register! Register for our live event while you still can.


Our discussion will be focused on trauma, PTSD and VNS. We hope to see you there! You can register for the webinar here.


We encourage everyone to spread the word to their network about investing and joining this exclusive online event!


Warmly,

Weaver Gaines
CEO
Evren Technologies

Live Q&A Webinar With Dr. Richard Marshall!

4 months ago


Hello Evren Community! 


Join Evren Technologies and Dr. Richard Marshall for a live investor Q&A webinar April 29th at 12:00 PM PST/3:00 PM EST.


There are less than 5 days left to register!


Our discussion will be focused on trauma, PTSD and VNS. We hope to see you there! You can register for the webinar here.


We encourage everyone to spread the word to their network about investing and joining this exclusive online event!



Warmly,

Weaver Gaines

CEO

Evren Technologies



Evren Technologies Awarded $172K Military Contract.

4 months ago


Evren Technologies Community,


Evren is thrilled to be partnered with Emory University and Dr. Doug Bremner, a leading PTSD researcher and an authority on acute stress, for this contract from the Army Medical Research and Development Command. This work presents an opportunity for significant improvements to managing stress response in both military and civilian applications.

In 2018, 28% of all medical evacuations were attributed to mental-health related symptoms. It is expected that Acute Stress Reactions (ASRs) will occur with increased frequency in far forward combat environments in future conflicts. Those who experience an ASR are at far greater risk of developing Post-Traumatic Stress Disorder (PTSD).  

ASRs are also common among first responders. It is estimated that police officers experience 7 traumas per year on average, and firefighters experience an average of 9 significant traumas in the first three years of service.

There are currently no FDA-approved treatments for ASRs. Existing treatments for PTSD, including psychotherapy and medications, have limited efficacy in many cases, and in others are ineffective. 



taVNS Reduces Stress Responses

Acute Stress Reactions (ASRs) are a normal human response to stressful or life-threatening situations. Unfortunately, ASRs can negatively impact cognitive, physiological and emotional functioning. They have also been connected to poor decision making and diminished task performance. Therefore, it is critical that we identify ways to reduce stress responses in order to maintain soldier performance in high threat environments.


Transcutaneous auricular vagal nerve stimulation (taVNS) is a non-invasive, painless treatment that can be self-administered using a small device designed to fit inside the ear and gently stimulate the vagus nerve. Preliminary research suggests that taVNS is associated with reduced stress reactivity.


The goals of this project are:

Goal 1: Demonstrate the effectiveness of the Phoenix® research device (CR-100) in maintaining performance after trauma or during extreme stress.

Goal 2: Improve device durability for use in hazardous or extreme environments and evaluate usability improvements.  

Goal 3: Develop relationships with Army and DoD personnel interested in utilizing the system and jointly develop requirements for the device and clinical trial.

Anticipated Benefits and Potential Commercial Applications

taVNS has demonstrated great efficacy in treating PTSD in clinical trials, resulting in the Evren Phoenix device having been granted the FDA’s “Breakthrough Device” designation. 


This technology has demonstrated the capability to reduce sympathetic response, reduce cortisol release, improve memory encoding capability, and decrease inflammation markers. This suggests that even after soldiers suffer significant emotional traumas, it could significantly mitigate acute stress response and improve functioning in far forward combat environments.


We intend to provide military field hospitals with an all-inclusive, multi-unit kit. We also plan to supply far forward battlefield medics with a small, single device pouch.

Civilian Market

Emergency responders commonly experience flashbacks of traumatic events. These flashbacks are referred to as "acute stress responses" (ASRs) and can occur among all types of emergency responders, including police, firefighters, and Emergency Medical Services (EMS). Beyond day to day experience, disasters can also cause acute stress reactions in both first responders and survivors.


ASRs create a substantial burden on first responders and limit the availability of the public services provided to the communities they serve. Without proper care, ASRs can lead to PTSD. 


A portable and rugged Acute Stress Reaction device would address a significant market opportunity in the disaster relief and response industries. 

Join Evren Technologies as an Early Investor

We need your support in the development and distribution of the Phoenix®️ device. Invest in Evren Technologies on StartEngine and support a post-traumatic stress disorder treatment for millions of PTSD sufferers. 

 


Warmly,

Weaver Gaines




Live Q&A Webinar With Dr. Richard Marshall!

4 months ago


Hello Evren Community! 


Join Evren Technologies and Dr. Richard Marshall for a live investor Q&A webinar April 29th at 12:00 PM PST/3:00 PM EST.


There’s only a week left to register!


Our discussion will be focused on trauma, PTSD and VNS. We hope to see you there! You can register for the webinar here.


We encourage everyone to spread the word to their network about investing and joining this exclusive online event.


Warmly,

Weaver Gaines
CEO
Evren Technologies

Meet the Visionaries Tackling Post-Traumatic Stress Disorder.

4 months ago


Evren Technologies Community,


Current treatments for PTSD include psychotherapy and pharmaceuticals; however, neither are consistently effective. 


About two-thirds of people treated with talk therapy do not see their symptoms improve, while a large percentage may experience worsening symptoms.


Evren is focused on providing the best possible care for patients living with PTSD,  and our team has extensive experience in research and development of biomedical devices, consulting, entrepreneurship, and medical technology.


In today's investor article, I want to take a moment to introduce you to the leaders who will be making a drug-free solution to PTSD widely available to the millions of sufferers in America who are still seeking treatment.

Weaver Gaines, Chairman and CEO

Weaver Gaines has over 40 years of entrepreneurial, management, and legal experience, including over 25 years as a founder, fund-raiser, and manager of start-up life science companies. Most recently, he was a co-founder and CEO of OBMedical Company, a medical device company that developed and received FDA clearance for an electronic maternal fetal monitor, which was acquired by Philips Healthcare in 2018.

Gaines received a BA from Dartmouth College and a JD from the University of Virginia School of Law and was an Infantry officer who served in Vietnam from 1969-70, with a final rank of Captain.

Neil Euliano, Chief Technology Officer

Neil Euliano has spent the past 20 years leading teams developing medical devices and technology. He is the chief designer and manager of the FDA cleared Philips Healthcare VentAssist team that developed intelligent decision support software for ventilated patients. He holds over 40 US patents and has ten more pending. In addition, he has a long history in managing multidisciplinary medical development teams and 19 years of experience managing R&D grants, including over $12M in industry and government funded research. His commercialization and entrepreneurial experience includes being the cofounder of two companies, both of which led to FDA clearance, commercial sales, and acquisition. He has been involved in the successful FDA clearance of more than 6 medical devices. 

Euliano holds a PhD in Signal Processing and Electrical Engineering, an MSEE in Electrical Engineering, and a BSE in Computer Science all from the University of Florida.


Kimberly A. Ramsey, Chief Financial Officer

A serial entrepreneur, with 30 years progressive corporate finance and operations experience Ramsey has played a key role in raising over $100 million, including several successful IPOs. Most recently, she has been providing executive consulting services to medical device start-ups as founder and president of Bio/Med CXO. As co-founder and Chief Financial Officer for OBMedical Company, she played a key role in forwarding a ground-breaking wireless fetal/maternal monitor for use in labor and delivery departments, raising over $10M in private equity, leading to a successful acquisition by Philips Healthcare. Prior to that, she was key to successful mergers and IPOs in the biotech, med device and high-tech arenas. Ramsey holds a BSAc from the Fisher School of Accounting at the University of Florida. 

Stephanie Warrington, Member of Board of Directors

Ms. Warrington has been an independent consultant since 2014, advising a wide range of early stage medtech and biotech companies in strategic and business planning, investor relations, licensing, product development and building early stage corporate infrastructure. She has over 25 years of experience in the healthcare industry, with the past 15 years being involved in cutting edge startups working to solve difficult healthcare challenges. She was a founder, president and director of TrueMotion Spine, Inc., a Co-founder and VP, Corporate Development for Xhale, Inc., and President of Synogen, Inc. She holds an MBA, an MHA, and a BS in Business Administration from the University of Florida.

Robert V. House, Member of Board of Directors

Dr. House is an independent consultant and was previously Senior Vice President, Government Contracts of Ology Bioservices, with over 20 years' experience leading the contract management and oversight process of major US Government contracts with various agencies including the DoD, NIH, HHS, and other federal entities. He is also a director of Arrevus, Inc. He has more than 76 peer reviewed publications, plus numerous review articles, book chapters, and books. In addition, he is an adjunct professor at George Mason University. Dr. House is a graduate of the University of North Carolina at Chapel Hill, where he received his BA (Zoology), his MS in Public Health, and his PhD (Medical Parasitology). He will play a major role in our non-dilutive financing initiative. 

Richard Ferrari, Member of Board of Directors

Richard Ferrari

Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Biotechnology. He has raised over a billion dollars for companies he has directly influenced and participated in approximately 1.5 billion dollars in acquisition events. 

Additionally, he has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. His most recent success, CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was acquired by Guidant for $350 million in November 1999. Mr. Ferrari was a co-founder of CTS and the force that led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history. Additionally, Rich was the co-founder of the MTG Group which developed Ensure femoral closure device which sold to J&J for $100 Mill returning 10x to investors and IVS which developed the Star Close and sold to Abbott for $100Mill also returning 10x to investors. He is also the co-founder of Transaortic, an integrated femoral sheath and embolic capture system for TAVR procedure which sold last year to Medtronic. He was also the Executive Chairman of SentreHeart where he led the acquisition to Atricure for $300Mill. 

Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. He holds a BS degree from Ashland University and an MBA from the University of South Florida.

Suha Jhaveri, Member of Board of Directors

Ms. Jhaveri is presently the Chief Commercial Officer and Head of Business Development of Leyden Labs. Previously she was VP, Market Development of Vir Biotechnology, Global Commercial Leader and New Product Planning for Ultragenyx Pharmaceuticals. Prior to that, she was the Chief Operating Officer of OBMedical Company, and held a variety of executive positions with biotech and tech companies as well as working as a consultant for Boston Consulting Group. She holds an MBA from Harvard, a MA in Economic Development from the University of Sussex, and a BA in International Relations from Stanford University.


Invest in Evren and Create a Positive Social Impact

Our team envisions a future in which those suffering from Post-Traumatic Stress Disorder can be treated effectively.  


We invite you to participate in our equity crowdfunding campaign. Please visit our raise page, where you can learn more about our mission to improve countless lives and bring a happier, healthier future to those in need.



Warmly,

Weaver Gaines




Live Q&A Webinar With Dr. Richard Marshall!

4 months ago


Hello Evren Community! 


Join Evren Technologies and Dr. Richard Marshall for a live investor Q&A webinar April 29th at 12:30 PM PST/3:30 PM EST.


Our discussion will be focused on trauma, PTSD and VNS.There are two weeks before we go live so register now while you still have the chance!


We hope to see you there! You can register for the webinar here.


We encourage everyone to spread the word to their network about investing and joining this exclusive online event!


Warmly,
Weaver Gaines
CEO
Evren Technologies




Our Community Joins In! | Insider Investment Notice

4 months ago

We’re excited to see our community come in and invest in Evren Technologies!

Our insiders have invested a total of $18,005.31 into this offering.


We hope you join us on our mission to create a better treatment for PTSD. Invest in Evren today!

Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.

Learn More About Evren Technologies!

4 months ago



Evren Technologies Community,


Neuroscience and psychology have improved significantly over the past decades. However, PTSD still remains a huge problem for returning veterans and the general population.


If we can treat PTSD with a pill, it would be great—but we can't. Antidepressants and other medications have been shown to offer only modest relief at best. Veterans, who are most likely to get the disorder, often find that their symptoms don't go away or come back repeatedly.


In fact, there are an estimated 60 million people in the United States who suffered from post-traumatic stress disorder last year alone.


Enter Evren.


Evren Technologies is revolutionizing the treatment of Post Traumatic Stress Disorder with our development of The Phoenix®️ earbud. The Phoenix®️ is the way we deliver non-invasive taVNS. Its sleek design and comfortable fit makes it easy for you to get started with your treatment plan right away.


The Phoenix®️ earbud provides therapy without drugs, surgery, or side effects. Our device is designed for those who have tried medications and other treatments, but have not experienced the results they need.


One of our pilot study participants states, “What do I have to lose? It’s not a drug that I’m putting in my system and it's not something that I’m smoking. So, if you’re telling me that you can put something in my ear and make me better, sign me up every day of the week!” 


More about The Phoenix:


  • The auricular branch of the vagus nerve targets only afferent fibers, sending signals straight to the brain without invasive surgery.


  • No study to date has reported a significant adverse side effect of therapy with taVNS.


  • Demonstrated a 91% responder rate in reducing the Clinician-Administered PTSD Scale (CAPS-5).


  • 100% of Phoenix® users wanted to continue using the device after the pilot trial and all of them were willing to pay out-of-pocket for it.


We are looking for like-minded individuals who want to create a positive social impact to invest in our first public offering.


If this sounds like you, we encourage you to visit our StartEngine raise page and join our community of early shareholders today. 



Warmly,

Weaver Gaines



Evren Technologies Surpasses $100K in Investments!

5 months ago


Evren Technologies Community,


We have some incredible news to share with you…


Thanks to the support of our rapidly growing investor community, we’ve just surpassed a major milestone in the first week of our equity crowdfunding journey:


Over $100K raised by early shareholders on StartEngine!


We’re honored to be able to grow alongside such an amazing group of investors who believe in our mission, and we want to thank all of you for your continued support as we work hard to make this vision a reality.


Evren is developing a device, the Phoenix®, which will provide personalized levels of vagal nerve stimulation to reduce PTSD symptom severity and improve quality of life. 


Help us bring comfort to the 15M Americans suffering from PTSD each year by investing in Evren Technologies on our raise page today.


We look forward to a strong campaign, and an even stronger partnership.


Warmly,
Weaver Gaines




Top Reasons to Invest in Evren’s PTSD Solution.

5 months ago


Evren Technologies Community,


In the past, mental health has not been taken seriously. As a result, there are limited resources for sufferers of mental illness. 


Evren Technologies is here to change that. We believe mental health matters.


Evren is developing a portable, non-invasive device for the millions of Americans with PTSD. Current treatments are not getting the job done, leaving 66% of patients still seeking relief.. Evren’s device, the Phoenix®, will provide personalized levels of vagal nerve stimulation to reduce PTSD symptom severity and improve quality of life without the harmful side effects seen with prescription drugs.


Whether it's a soldier returning from war, a survivor of traumatic violence or abuse, an individual who has experienced a serious car accident, or anyone else exposed to traumatic experiences and suffering from the effects of PTSD, Evren's technology can be used by anyone, anytime and anywhere to manage their disorder.


As you may have heard, Evren Technologies is currently raising capital via StartEngine’s equity crowdfunding platform. Here are a few compelling reasons to join our community of early shareholders.

Why invest in Evren? 

  • Evren's device, the Phoenix®, was recently awarded Breakthrough Device Designation by the FDA, demonstrating that it could provide better treatment than the current standard of care in the serious, life-threatening condition of Post-Traumatic Stress Disorder.


  • Evren is the recipient of the SBIR Phase I award for the development of a "Programmable tVNS research device for PTSD and related conditions."


  • Revolutionary technology for a massive, untapped market: Post-Traumatic Stress Disorder is a $22.5 billion-dollar market with 66% of those suffering seeking new treatment options.


  • 15 million Americans experience post-traumatic stress disorder in a given year, and over 60 million Americans suffered from PTSD during the height of the COVID shutdown.


  • All 100% of Phoenix® users wanted to continue using the device after the pilot trial, and all of them were willing to pay out-of-pocket for it.

Join Evren Technologies as an Early Shareholder

What are you waiting for? Head over to our StartEngine raise page and take advantage of our latest offering for as little as $399. We thank you in advance for your support!


Warmly,
Weaver Gaines



Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}
Startengine logo black
©2022 All Rights Reserved
Important Message
IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.
www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA.
Investment opportunities posted and accessible through the site are of three types:
1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks. 
Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of Use and Privacy Policy, as may be amended from time to time without notice or liability.
Canadian Investors
Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors.
Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.
California Investor Only - Do Not Sell My Personal Information